Metabolism of all-trans-retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy- to 4-keto-retinoic acid

doi:10.1016/0003-9861(80)90293-3

Archives of Biochemistry and Biophysics

Volume 199, Issue 2, February 1980, Pages 374-383

https://doi.org/10.1016/0003-9861(80)90293-3 Get rights and content

Abstract

Experimental evidence indicates that the major pathway of retinoic acid metabolism in hamster liver microsomes follows the sequence: retinoic acid → 4-hydroxy-retinoic acid → 4-keto-retinoic acid → more polar metabolites. Using all-trans-[10-³H]retinoic acid, it can be shown by reverse-phase high pressure liquid chromatographic analysis that the first and last steps of this sequence require NADPH, whereas the oxidation of 4-hydroxy to 4-keto-retinoic acid is NAD⁺ (or NADP⁺) dependent. Both NADPH-dependent steps, but not the NAD⁺-dependent dehydrogenase reaction, are strongly inhibited by carbon monoxide. The metabolism of retinoic acid but not of 4-hydroxy-retinoic acid is highly dependent on the vitamin A regimen of the animal. Retinoic acid is rapidly metabolized by liver microsomes either from vitamin A-normal hamsters or from vitamin A-deficient hamsters that have been pretreated with retinoic acid, but not by microsomes from vitamin A-deficient animals; in direct contrast, the rate of metabolism of 4-hydroxy-retinoic acid is equivalent in each of these microsomal preparations. Analysis of the kinetics of these reactions yields the following Michaelis constants with respect to the retinoid substrates: retinoic acid, 1 × 10⁻⁶m; 4-hydroxy-retinoic acid, 2 × 10⁻⁵m; and 4-keto-retinoic acid, 1 × 10⁻⁷m. The 4-hydroxy to 4-keto-retinoic acid oxidation has been shown to be experimentally irreversible, to have a K_mNAD⁺of 2 × 10⁻⁵m, to be strongly inhibited by NADH, and to be unaffected by the presence of retinoic acid or its 4-keto-derivative in an equimolar ratio to the 4-hydroxy-substrate.

References (29)

M. Zile et al.
J. Nutr
(1968)
C.A. Frolik et al.
J. Lipid Res
(1978)
A.M. McCormick et al.
Anal. Biochem
(1978)
C.A. Frolik et al.
J. Biol. Chem
(1978)
A.B. Roberts et al.
J. Biol. Chem
(1979)
W. Levin et al.
Biochem. Pharmacol
(1969)
M.M. Bradford
Anal. Biochem
(1976)
Y.L. Ito et al.
J. Lipid Res
(1974)
A.B. Roberts et al.
J. Biol. Chem
(1979)
H.J. Lee et al.
Biochim. Biophys. Acta
(1971)

B. Hurlock et al.

Arch. Biochem. Biophys

(1959)

P.E. Dunagin et al.

Biochim. Biophys. Acta

(1966)

K. Lippel et al.

J. Lipid Res

(1968)

J.E. Dowling et al.

Cited by (109)

Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases
2019, Pharmacology and Therapeutics
Citation Excerpt :
However, the formation of 4-oxo-atRA likely requires an alcohol dehydrogenase enzyme in tissue and cell systems for the second oxidization step after initial 4-hydroxylation. Studies in HepG2 cells and microsomes have shown that 4-oxo-atRA formation from 4-OH-atRA, is mainly mediated by NAD+-dependent enzymes and not by CYP26A1 (Topletz et al., 2015), and early studies in hamster liver microsomes showed that 4-oxo-RA formation was mediated by an ADH enzyme (Roberts, Lamb, & Sporn, 1980). However, the identity of the enzyme(s) forming 4-oxo-RA remains to be determined.
The Cytochrome P450 (CYP) family 26 enzymes contribute to retinoic acid (RA) metabolism and homeostasis in humans, mammals and other chordates. The three CYP26 family enzymes, CYP26A1, CYP26B1 and CYP26C1 have all been shown to metabolize all-trans-retinoic acid (atRA) it's 9-cisRA and 13-cisRA isomers and primary metabolites 4-OH-RA and 4-oxo-RA with high efficiency. While no crystal structures of CYP26 enzymes are available, the binding of various ligands has been extensively explored via homology modeling. All three CYP26 enzymes are inducible by treatment with atRA in various prenatal and postnatal tissues and cell types. However, current literature shows that in addition to regulation by atRA, CYP26 enzyme expression is also regulated by other endogenous processes and inflammatory cytokines. In humans and in animal models the expression patterns of CYP26 enzymes have been shown to be tissue and cell type specific, and the expression of the CYP26 enzymes is believed to regulate the formation of critical atRA concentration gradients in various tissue types. Yet, very little data exists on direct disease associations of altered CYP26 expression or activity. Nevertheless, data is emerging describing a variety of human genetic variations in the CYP26 enzymes that are associated with different pathologies. Interestingly, some of these genetic variants result in increased activity of the CYP26 enzymes potentially leading to complex gene-environment interactions due to variability in dietary intake of retinoids. This review highlights the current knowledge of structure-function of CYP26 enzymes and focuses on their role in human retinoid metabolism in different tissues.
Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases
2012, Biochemical Pharmacology
Citation Excerpt :
These differences suggest that formation of oxo-compounds is more abundant in whole cells than in recombinant microsomes. It has previously been shown that a non-NADPH dependent enzyme is mainly responsible for 4-oxo-RA formation [39]. Thus the clearance of atRA and its active metabolites appears to involve other enzymes as well as CYP26 isoforms.
All-trans-retinoic acid (atRA) is an important signaling molecule in all chordates. The cytochrome P450 enzymes CYP26 are believed to partially regulate cellular concentrations of atRA via oxidative metabolism and hence affect retinoid homeostasis and signaling. CYP26A1 and CYP26B1 are atRA hydroxylases that catalyze formation of similar metabolites in cell systems. However, they have only 40% sequence similarity suggesting differences between the two enzymes. The aim of this study was to determine whether CYP26A1 and CYP26B1 have similar catalytic activity, form different metabolites from atRA and are expressed in different tissues in adults. The mRNA expression of CYP26A1 and CYP26B1 correlated between human tissues except for human cerebellum in which CYP26B1 was the predominant CYP26 and liver in which CYP26A1 dominated. Quantification of CYP26A1 and CYP26B1 protein in human tissues was in agreement with the mRNA expression and showed correlation between the two isoforms. Qualitatively, recombinant CYP26A1 and CYP26B1 formed the same primary and sequential metabolites from atRA. Quantitatively, CYP26B1 had a lower K_m (19 nM) and V_max (0.8 pmol/min/pmol) than CYP26A1 (K_m = 50 nM and V_max = 10 pmol/min/pmol) for formation of 4-OH-RA. The major atRA metabolites 4-OH-RA, 18-OH-RA and 4-oxo-RA were all substrates of CYP26A1 and CYP26B1, and CYP26A1 had a 2–10-fold higher catalytic activity towards all substrates tested. This study shows that CYP26A1 and CYP26B1 are qualitatively similar RA hydroxylases with overlapping expression profiles. CYP26A1 has higher catalytic activity than CYP26B1 and seems to be responsible for metabolism of atRA in tissues that function as a barrier for atRA exposure.
Multiple retinoic acid response elements cooperate to enhance the inducibility of CYP26A1 gene expression in liver
2010, Gene
CYP26A1, which catalyzes the oxidation of all-trans (at)-retinoic acid (RA), is induced moderately by RA in numerous tissues, but is highly responsive in liver. To understand this difference, we have examined the CYP26A1 gene sequence, identified multiple RA response elements (RAREs) and tested them functionally in HepG2 cells as model hepatocytes, and in the liver of vitamin A (VA)-adequate and -deficient rats. Analysis of a 2.2 kbp 5'-flanking region upstream of the CYP26A1 transcription start site (TSS) identified 3 conserved hexameric direct repeat-5 elements, RARE1, -2 and -3, and a half site, RARE4. The full-length promoter containing all 4 elements was sufficient and necessary to increase promoter activity similar to levels of endogenous CYP26A1 mRNA produced in HepG2 cells treated with at-RA. In DNA binding and chromatin immunoprecipitation assays, the binding of RARs to the proximal RARE1 and distal RARE2, -3, and -4 regions of the CYP26A1 promoter was increased in RA-treated HepG2 cells, and greater in VA-sufficient than VA-deficient liver. Moreover, RA increased the binding of RNA polymerase-II in the distal as well as the proximal region, indicating that the distal region may be looped to become positioned close to the TSS, a process favored by retinoic acid receptors. The results support a cooperative model in which the functioning of multiple RAREs may account for the strong inducibility of CYP26A1 in liver, which, in turn, may be important physiologically for restoring retinoid homeostasis when the concentration of RA rises.
Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin™ and full thickness model from Episkin™
2009, Journal of Steroid Biochemistry and Molecular Biology
Episkin™ and full thickness model from Episkin™ (FTM) are human skin models obtained from in vitro growth of keratinocytes into the five typical layers of the epidermis. FTM is a full thickness reconstructed skin model that also contains fibroblasts seeded in a collagen matrix.
To assess whether enzymes involved in chemical detoxification are expressed in Episkin™ and FTM and how their levels compare with the human epidermis, dermis and total skin.
Quantification of the mRNA expression levels of phases 1 and 2 metabolizing enzymes in cultured Episkin™ and FTM and human epidermis, dermis and total skin using Realtime PCR.
The data show that the expression profiles of 61 phases 1 and 2 metabolizing enzymes in Episkin™, FTM and epidermis are generally similar, with some exceptions. Cytochrome P450-dependent enzymes and flavin monooxygenases are expressed at low levels, while phase 2 metabolizing enzymes are expressed at much higher levels, especially, glutathione-S-transferase P1 (GSTP1) catechol-O-methyl transferase (COMT), steroid sulfotransferase (SULT2B1b), and N-acetyl transferase (NAT5). The present study also identifies the presence of many enzymes involved in cholesterol, arachidonic acid, leukotriene, prostaglandin, eicosatrienoic acids, and vitamin D3 metabolisms.
The present data strongly suggest that Episkin™ and FTM represent reliable and valuable in vitro human skin models for studying the function of phases 1 and 2 metabolizing enzymes in xenobiotic metabolisms. They could be used to replace invasive methods or laboratory animals for skin experiments.
Cytochrome P450: A target for drug development for skin diseases
2004, Journal of Investigative Dermatology
Citation Excerpt :
RA metabolizes via the hydroxylation of its cyclohexenyl moiety resulting in the formation of inactive 4-hydroxy-RA that further oxidized to keto-RA and other polar metabolites. It has been widely shown that these reactions are CYP dependent (Roberts et al, 1980;Williams and Napoli, 1985, 1987). Studies have shown that the in vitro hydroxylation of RA is catalyzed by the CYP (Roberts et al, 1991;Martini and Murray, 1993).
Enzymes of the cytochrome P450 (P450 or CYP) super family are the most versatile and important class of drug-metabolizing enzymes that are induced in mammalian skin in response to xenobiotic exposure. At the same time, CYP have numerous important roles in endogenous and exogenous substrate metabolism in the skin. For example, they participate in the metabolism of therapeutic drugs, fatty acids, eicosonoids, sterols, steroids, vitamin A, and vitamin D, to name a few. In addition, in some skin diseases, for example in psoriasis, many CYP are elevated. CYP are the target of special interest in the development of drugs for skin diseases because most, if not all, drugs available in the armamentarium of the dermatologists are either substrate, inducer, or inhibitor of this enzyme family. The functional significance of drug metabolism in skin and the implication of CYP in skin pathology and therapy is an area for future investigation. A detailed insight into the mechanism of action of various cutaneous CYP, being capable of modulating the drug bioavailability, will be helpful in the development of better strategies for novel therapy against constantly increasing skin disorders. This brief review discusses some of these perspectives and suggests additional work in this research area with regard to the expression and modulation of CYP in mammalian skin as well as their implication in dermatological disorders and the therapy of skin diseases.
Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: A model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid
2002, Toxicology and Applied Pharmacology
The remarkable toxicity of (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid (TTNPB) compared to all trans-retinoic acid (tRA) is due to multiple factors, including reduced affinities for cytosolic binding proteins (CRABPs), resistance to metabolism, and prolonged nuclear receptor activation. To further investigate the role of half-life in retinoid toxicity, experiments were performed to determine whether, and to what extent, inhibition of tRA metabolism by liarozole increased its toxicity comparable to that of TTNPB in the mouse limb bud system. Liarozole is a known inhibitor of tRA 4-hydroxylation (CYP26). In the absence of liarozole, the IC50 for inhibition of chondrogenesis by tRA was 140 nM compared to 0.3 nM for TTNPB, a 467-fold difference. Following the addition of liarozole (10⁻⁶ M) to limb bud cultures, the potency of tRA to inhibit chondrogenesis was increased approximately 14-fold (IC50 of 9.8 nM). Although liarozole markedly increased toxicity of tRA in mouse limb bud micromass cultures, tRA metabolism was inhibited only about 10%. These results indicate that a relatively minor decrease in the metabolism of tRA in the mouse limb bud system is associated with a marked enhancement of toxicity that is likely related to the prolongation of tRA half-life during a critical period of development. Thus, the prolonged half-life of TTNPB is the most significant factor contributing to the remarkable teratogenicity of this synthetic aromatic retinoid.

View all citing articles on Scopus

^☆: An abstract of this work appeared in Fed. Proc.38, 761 (1978).

View full text

Metabolism of all-trans-retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy- to 4-keto-retinoic acid☆

Abstract

J. Nutr

J. Lipid Res

Anal. Biochem

J. Biol. Chem

J. Biol. Chem

Biochem. Pharmacol

Anal. Biochem

J. Lipid Res

J. Biol. Chem

Biochim. Biophys. Acta

Arch. Biochem. Biophys

Biochim. Biophys. Acta

J. Lipid Res